Marshall Wace’s Medifast MED Stock Holding History

Marshall Wace’s Portfolio MED Stock Details MED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.56M	Buy	+241,649	New	+$2.79M	﹤0.01%	1717
2025 Q2	–	Sell	-166,199	Closed	-$2.24M	–	2978
2025 Q1	$2.24M	Buy	166,199 +61,973	+59%	+$931K	﹤0.01%	1425
2024 Q4	$1.84M	Buy	+104,226	New	+$1.93M	﹤0.01%	1474
2023 Q4	–	Sell	-12,500	Closed	-$936K	–	2441
2023 Q3	$936K	Sell	12,500 -16,103	-56%	-$1.43M	﹤0.01%	1520
2023 Q2	$2.64M	Buy	+28,603	New	+$2.55M	0.01%	1276
2022 Q3	–	Sell	-1,832	Closed	-$331K	–	3615
2022 Q2	$331K	Buy	+1,832	New	+$328K	﹤0.01%	2987
2022 Q1	–	Sell	-36,425	Closed	-$7.63M	–	3737
2021 Q4	$7.63M	Buy	+36,425	New	+$7.53M	0.01%	1063
2019 Q4	–	Sell	-74,006	Closed	-$7.67M	–	1927
2019 Q3	$7.67M	Sell	74,006 -494	-0.7%	-$53.1K	0.06%	369
2019 Q2	$9.56M	Buy	74,500 +46,740	+168%	+$6.49M	0.08%	293
2019 Q1	$3.54M	Buy	27,760 +14,659	+112%	+$1.86M	0.03%	569
2018 Q4	$1.64M	Buy	+13,101	New	+$2.24M	0.02%	777
2018 Q2	–	Sell	-6,900	Closed	-$645K	–	780
2018 Q1	$645K	Buy	+6,900	New	+$516K	0.03%	311
2016 Q3	–	Sell	-75,823	Closed	-$2.52M	–	1054
2016 Q2	$2.52M	Buy	+75,823	New	+$2.45M	0.02%	534

Other funds holding MED

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

SCP

Steamboat Capital Partners Rye, New York $468M AUM 80.81% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Marshall Wace's MED Position: Q2 2026 in Review

Marshall Wace opened a new position in Medifast (MED) in Q2 2026: 241,649 shares worth $2.56M. The stake represents ﹤0.01% of the portfolio and ranks #1717 among its holdings. This is a return to the name: Marshall Wace previously reported a position in MED as recently as Q1 2025.

Marshall Wace first reported a position in MED in Q2 2016 and has held it in 13 quarters since. The position peaked at $9.56M in Q2 2019. 113 funds tracked by Wall St. Rank hold MED as of Q2 2026.

Marshall Wace held 241,649 shares of Medifast worth $2.56M as of Q2 2026.
Medifast was a new Marshall Wace position in Q2 2026.
Medifast made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #1717 holding.
Marshall Wace first reported a position in Medifast in Q2 2016 and has held it in 13 quarters since.
Marshall Wace's Medifast position peaked at $9.56M in Q2 2019.
113 funds tracked by Wall St. Rank held Medifast as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.